 |
answer text |
<p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting
the uptake of 12 high performing products, with the potential to improve the lives
of up to 500,000 patients per year and save the National Health Service £30 million
per year in England. All the products currently being supported by the AAC have been
recommended by the National Institute for Health and Care Excellence, and therefore
evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The
AAC board met on 26 June and had a positive discussion about future products and expects
to announce further products later this year.</p><p>The AAC will consider the following
areas of interest when determining which products to support:</p><p>- evidence of
clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>-
application to large populations or high budget impact; and</p><p>- enabling a novel
mode of action or enabling significant changes to the care pathway.</p><p> </p><p>
</p>
|
|
